Related Experiment Video

Updated: Mar 29, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms

Pui-Kei Wu1, Jong-In Park1

  • 1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI.

Seminars in Oncology
|November 29, 2015
PubMed

Insights

Aberrant activation of the Raf/MEK/ERK pathway drives cancer. MEK1/2 inhibitors offer a promising therapeutic strategy, with many selective options now available for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant activation of the Raf/MEK/ERK signaling pathway is a hallmark of many human cancers.
  • This pathway's dysregulation drives tumor cell proliferation and survival, making it a critical therapeutic target.
  • While RAF, MEK1/2, and ERK1/2 are targets, MEK1/2 have shown particular promise for inhibitor development.

Purpose of the Study:

  • To review MEK1/2 inhibitors studied for their mechanisms and therapeutic potential in cancer.
  • To discuss key structural features of MEK1/2 relevant to inhibitor efficacy.
  • To explore current challenges and future directions for MEK1/2 inhibitor-based cancer therapy.

Main Methods:

  • Literature review of MEK1/2 inhibitors.
  • Analysis of inhibitory mechanisms and therapeutic evaluations.
  • Discussion of structural characteristics influencing inhibitor efficacy.

Main Results:

  • Significant success has been achieved in developing MEK1/2-specific inhibitors, particularly ATP-noncompetitive ones.
  • Numerous potent and selective MEK1/2 inhibitors are available and have undergone therapeutic evaluation.
  • Key structural features of MEK1/2 are crucial for the efficacy of these inhibitors.

Conclusions:

  • MEK1/2 inhibitors represent a rational and effective therapeutic strategy for various cancers.
  • Continued research into MEK1/2 inhibitors, addressing current challenges, holds promise for advancing cancer treatment.
  • Understanding structural determinants is vital for optimizing the design and application of these advanced inhibitors.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
95.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
43
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.3K